In the TI arm, the median CD4 cell count had decreased compared with baseline at the three time-points www.selleckchem.com/products/dinaciclib-sch727965.html (−39.0% at month 12; −45.6% at month 24, and −45.9% at month 36; all comparisons P < 0.001), with no changes in the TC arm. Compared with the baseline value, the viral load had increased at month 12 in the TI arm, and remained higher at months 24 and 36 (P < 0.001

for all comparisons). In keeping with the study protocol, cART had to be reintroduced in five patients (25%) in the TI arm. The statistical analysis excluding these patients (data not shown) did not differ from the data presented. In the TI arm, total-c, LDL-c and HDL-c-values had decreased relative to baseline at all time-points (P < 0.001 for all comparisons) (Fig. 2). In the TC arm, no changes were observed in total-c or LDL-c, whereas HDL-c had increased at month 12 (median 6.7%; IQR −4.0, 21.4%;

P = 0.038), with no changes at month 24 or 36. The comparison between arms showed that total-c, LDL-c and HDL-c were higher in the TC arm at the three study time-points PI3K inhibitor (Fig. 2). Nevertheless, no changes in total-c/HDL-c were observed in either arm. Triglycerides did not change in the TI arm, whereas a decrease was observed in the TC arm at months 24 and 36 compared with baseline (P = 0.018 and P = 0.033, respectively), with no differences between arms. VL† (r = 0.545,

P < 0.001) HDL-c* (r = −0.359, P = 0.023) VL‡ (r = 0.809, P < 0.001) HDL-c* (r = −0.435, P = 0.005) CD4† (r = 0.294, P = 0.036) HDL-c† (r = −0.380, P = 0.007) HDL-c* (r = −0.418, P = 0.007) CD4* (r = 0.308, P = 0.023) CD4¶ (r = 0.394, P = 0.004) HDL-c* (r = −0.440, P = 0.004) HDL-c¶ (r = −0.434, P = 0.002) Total-c (β = −782.4; CI −1525.6, −39.21; P = 0.040) CD4¶ (β = 2.73; CI 1.58, 3.87; P < 0.001) HDLc¶ (β = −1256.7; CI −1942.7, −570.8; P < 0.001) Total-c* (r = 0.327, P = 0.016) Δ Total-c§ (r = −0.438, P = 0.001) Δ HDL-c§ of (r = −0.339, P = 0.035) LDL-c* (r = 0.421, P = 0.011) Δ LDL-c§ (r = −0.392, P = 0.026) Age (r = 0.318, P = 0.019) LDL-c* (β = 467.4; CI 52.0, 882.9; P = 0.029) Δ HDL-c§ (β = −1298.6; CI −2282.4, −314.9; P = 0.012) Age (β = 71.2; CI 13.8, 128.6; P = 0.017) TG* (r = 0.277, P = 0.049) HDL-c† (r = −0.292, P = 0.039) Age (r = 0.346, P = 0.011) Total-c¶ (r = 0.351, P = 0.012) LDL-c¶ (r = 0.365, P = 0.015) Age (β = 181.2; CI 33.5, 328.8; P = 0.017) Sex (male) (β = 2715.7; CI 23.5, 5407.8; P = 0.048) Total-c¶ (r = 0.281, P = 0.048) c-HDL¶ (r = 0.456, P = 0.001) c-LDL¶ (r = 0.512, P < 0.